There are 2 new MSS-CRC immunotherapy trials announced today (neither is recruiting yet - but announced. I'l post as 2 separate posts. Here is #1.
#1 - This one makes a lot of scientific sense. It is for liver-only resectable metastases patients. It gives a PDL1 & CTLA-4 inhibitors + FOLFOX prior to surgical resection. Goal: To have the immune system wipe up any micro-metastases left over after FOLFOX and surgery. FOLFOX is key to help train the immune system followed by immune activation by anti-PDL1 and anti-CTL4 immnotherapies. NCT02754856
https://clinicaltrials.gov/ct2/show/NCT ... 856&rank=1